Redirecting to http://dergipark.org.tr/_fragment?_hash=FseKFubyunWdMUWLgJXRbaP0gh2utrBr0ARcjg-c8ig&_path=id%3D1487298%26_format%3Dhtml%26_locale%3Den%26_controller%3DApp%255CController%255CSite%255CArticleController%253A%253AesiArticleStats.
Research Article
BibTex RIS Cite

Age distribution of patients with multiple High-Risk Human Papilloma Virus (HR-HPV) genotypes and HPV vaccine recommendations by age

Year 2024, Volume: 9 Issue: 3, 80 - 84, 25.10.2024

Gülçin Çetin Uysal , Nil Tekin

https://doi.org/10.22391/fppc.1487298

Abstract

Introduction: The aim of this study to identify the age distribution of patients with multiple high risk Human Papilloma Virus (HR-HPV) genotypes and to evaluate HPV vaccination programs through age distribution.
Methods: Patients between the ages of 20-70, who had cervical screening (cervical smear) and HPV genotype tests between January 2017 and December 2021 in Gynecology and Obstetrics Department in Tınaztepe University Hospital, were included in this study. HR-HPV genotype tests and age information which were performed evaluated retrospectively.
Results: The study consisted of 66 patients analysis with multiple HR-HPV genotypes. The median age of the patients with multiple HR- HPV was found to be 32.6 years old. The most frequent combination of multiple HR-HPV was found two sub-types of HR-HPV (66.7%), median age was found as 36.6 years old. In this study the frequency for three sub-types of HR-HPV was found 24.2% and median age for this group was found to be 34.7
years old. We found frequency in patients with four or more sub-types of HR-HPV as 9.1%, and the median age for this group as 33.1 years old was found.
Conclusion: The most common cause of cervical cancer is HPV infection. Multiple HR-HPV infection progression may promote high risk cervical lesions and neoplasia. HPV genotype testing results considering combination of subtypes may direct individual treatment, follow-up protocols for patients. HPV vaccination research may comprise multiple HR-HPV subtypes relations and age distribution for optimal immunization.

Keywords

Human Papilloma Virus Papillomavirus Vaccines Genotype

Ethical Statement

The research was approved by İzmir Tınaztepe University (İZTÜ) Ethics Committee (İZTÜ - Non-Invasive Clinical Research Ethics Committee Decision Form: (770/02- 15.01.2021).

Supporting Institution

No financial support was received from any instution or person for this studyThe authors declared no conflict of interest regarding this article.

Thanks

The authors would like to thank all the participant of the study

References

  • 1. World Health Organization. Global Strategy to Accelerate the Elimination of Cervical Cancer as a Public Health Problem. Geneva: World Health Organization; 2020. License: CC BY-NC-SA 3.0 IGO.
  • 2. Doorbar J, Egawa N, Griffin H, Kranjec C, Murakami I. Human papillomavirus molecular biology and disease association. Rev Med Virol. 2015;25(suppl 1):2-23. https://doi.org/10.1002/rmv.1822
  • 3. Bouvard V, BaanR, StraifK, Grosse Y, Secretan B, El Ghissassi F et al. A review of human carcinogens -part b: biological agents. Lancet Oncol. 2009;10(4):321-322. https://doi.org/10.1016/S1470-2045(09)70096- 8
  • 4. Pandey S, Chandravati C. Human papillomavirus-mediated cervical cancer awareness and gardasil vaccination: a pilot survey among north Indian women. J Community Health. 2013;38:907- 10. https://doi.org/10.1007/s10900-013-9697-6
  • 5. Dalstein V, Riethmuller D, Prétet JL, Le Bail CK, Sautière JL, Carbillet JP, et al. Persistence and load of high-risk HPV are predictors for development of high-grade cervical lesions: a longitudinal French cohort study. Int J Cancer. 2003;106(3):396-403. https://doi.org/10.1002/ijc.11222
  • 6. Dong L, Wang MZ, Zhao XL, Feng RM, Hu SY, Zhang Q, et al. Human papillomavirus viral load as a useful triage tool for non- 16/18 high-risk human papillomavirus positive women: a prospective screening cohort study. Gynecol Oncol. 2018;148(1):103- 110. https://doi.org/10.1016/j.ygyno.2017.11.016
  • 7. Luo H, Belinson JL, Du H, Liu Z, Zhang L, Wang C, et al. Evaluation of viral load as a triage strategy with primary high-risk human papillomavirus cervical cancer screening. J Low Genit Tract Dis. 2017;21(1):12- 16. https://doi.org/10.1097/LGT.0000000000000277
  • 8. Li Y, Wang H, Zhang Y, Jing X, Wu N, Hou Y, Hao C. Correlation between Multi-type human papillomavirus infections and viral loads and the cervical pathological grade. Int J Gynecol Obstet. 2021;152(1):96- 102. https://doi.org/10.1002/ijgo.13406
  • 9. Zeng Z, Austin RM, Wang L, Guo X, Zeng Q, Zheng B, Zhao C. Nationwide prevalence and genotype distribution of high-risk human papillomavirus infection in China. Am J Clin Pathol. 2022;157(5):718-23. https://doi.org/10.1093/ajcp/aqab181
  • 10. De Brot L, Pellegrini B, Moretti ST, Carraro DM, Soares FA, Rocha RM, et al. Infections with multiple high-risk HPV types are associated with high-grade and persistent low-grade intraepithelial lesions of the cervix. Cancer Cytopathol. 2017;125(2):138- 143. https://doi.org/10.1002/cncy.21789
  • 11. American Cancer Society, Risk Factors for Cervical Cancer. Available at: https://www.cancer.org/cancer/types/cervical-cancer/causes-risks-prevention/risk-factors.html (Access Date: June 10, 2024).
  • 12. Simen-Kapeu A, KatajaV, YliskoskiM, Syrjänen K, Dillner J, Koskela P, et al. Smoking impairs human papillomavirus (HPV) type 16 and 18 capsid antibody response following natural HPV infection. Scand J Infect Dis. 2008;40(9):745-75. https://doi.org/10.1080/00365540801995360
  • 13. AguayoF, Muñoz JP, Perez-Dominguez F, Carrillo-Beltrán D, Oliva C, CalafGM, et al. High-risk human papillomavirus and tobacco smoke interactions in epithelial carcinogenesis. Cancers. 2020;12(8):2201. https://doi.org/10.3390/cancers12082201
  • 14. Schmitt M, Depuydt C, Benoy I, Bogers J, Antoine J, Arbyn M, Pawlita M. Multiple human papillomavirus infections with high viral loads are associated with cervical lesions but do not differentiate grades of cervical abnormalities. J Clin Microbiol. 2013;51(5):1458-64. https://doi.org/10.1128/JCM.00087- 13
  • 15. Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol. 2012;137(4):516-42. https://doi.org/10.1309/AJCPTGD94EVRSJCG
  • 16. Kim J, Kim M, Park JY. Evaluation of the characteristics of multiple human papillomavirus (HPV) infections identified using the BD Onclarity HPV assay and comparison with those of single HPV infection. J Pathol Transl Med. 2022;56(5):289-93. https://doi.org/10.4132/jptm.2022.08.02
  • 17. Trottier H, Mahmud S, Costa MC, Sobrinho JP, Duarte-Franco E, Rohan TE, et al. Human papillomavirus infections with multiple types and risk of cervical neoplasia. Cancer Epidemiol Biomarkers Prev. 2006;15(7):1274-80. https://doi.org/10.1158/1055-9965.EPI-06-0129
  • 18. Na J, Li Y, Wang J, Wang X, Lu J, Han S. The correlation between multiple HPV infections and the occurrence, development, and prognosis of cervical cancer. Front Microbiol. 2023;14:1220522. https://doi.org/10.3389/fmicb.2023.1220522
  • 19. De Brot L, Pellegrini B, Moretti ST, Carraro DM, Soares FA, Rocha RM, et al. Infections with multiple high‐risk HPV types are associated with high‐grade and persistent low‐grade intraepithelial lesions of the cervix. Cancer Cytopathol. 2017;125(2):138-43. https://doi.org/10.1002/cncy.21789
  • 20. World Health Organization, One in Three Men Worldwide Are Infected with Genital Human Papillomavirus. Available at:https://www.who.int/news/item/01-09-2023-one-in-three-men-worldwide- are-infected-with-genital-human-papillomavirus (Access Date: June 10, 2024).
  • 21. World Health Organization, Human papillomavirus vaccines: WHO position paper, December 2022. Available at: https://www.who.int/publications/i/item/who-wer9750-645-672 (Access Date: June 10, 2024).

Çok sayıda yüksek riskli Human Papilloma Virüs (HR-HPV) genotipi saptanan hastalarda yaş dağılımı ve HPV aşılama yaş önerileri

Year 2024, Volume: 9 Issue: 3, 80 - 84, 25.10.2024

Gülçin Çetin Uysal , Nil Tekin

https://doi.org/10.22391/fppc.1487298

Abstract

Giriş: Bu çalışmanın amacı, birden fazla yüksek riskli Human Papilloma Virüsü (HR-HPV) genotipine sahip hastaların yaş dağılımını belirlemek ve yaş dağılımları üzerinden HPV aşılama programlarını değerlendirmektir.
Yöntem: Bu çalışmaya Tınaztepe Üniversitesi Hastanesi Kadın Hastalıkları ve Doğum Kliniğinde Ocak 2017 ile Aralık 2021 tarihleri arasında servikal smear ve HPV genotip testleri yapılan 20-70 arası hastalar dahil edildi. HR-HPV genotiplendirme test sonuçları ve hastaların yaş dağılımları geriye dönük olarak değerlendirildi.
Bulgular: Çalışma birden fazla HR-HPV genotipine sahip 66 hastanın analizini içermektedir. Çoklu HR-HPV tanısı alan hastaların ortalama yaşı 32,6 olarak belirlendi. Çoklu HR-HPV saptanan hastalarda en sık kombinasyon iki alt tip birlikteliği (%66,7) olarak saptandı, ortalama yaş 36,6 olarak belirlendi. Bu çalışmada HR-HPV üç alt tip birlikteliği %24,2 ve ortalama yaş 34,7 olarak saptandı. HR-HPV dört veya daha fazla alt tip birlikteliği olan hastaların sıklığı %9,1 ve ortalama yaş 33,1 olarak bulundu.
Sonuç: Serviks kanserinin en sık nedeni HPV enfeksiyonudur. Çoklu HR-HPV enfeksiyonu varlığı, yüksek riskli servikal lezyonlara ve neoplaziye ilerlemeye yol açabilir. Hastalar, çoklu HR-HPV genotip test sonuçları göz önüne alınarak bireysel tedavi ve takip protokollerine yönlendirilebilir. HPV aşılama araştırmaları, en uygun bağışıklama sağlamak için serviks kanseri ile birden fazla HR-HPV alt tipi ilişkisini ve yaş dağılımlarını içerebilir.

Keywords

Human Papilloma Virüs Papilloma aşıları Genotip

References

  • 1. World Health Organization. Global Strategy to Accelerate the Elimination of Cervical Cancer as a Public Health Problem. Geneva: World Health Organization; 2020. License: CC BY-NC-SA 3.0 IGO.
  • 2. Doorbar J, Egawa N, Griffin H, Kranjec C, Murakami I. Human papillomavirus molecular biology and disease association. Rev Med Virol. 2015;25(suppl 1):2-23. https://doi.org/10.1002/rmv.1822
  • 3. Bouvard V, BaanR, StraifK, Grosse Y, Secretan B, El Ghissassi F et al. A review of human carcinogens -part b: biological agents. Lancet Oncol. 2009;10(4):321-322. https://doi.org/10.1016/S1470-2045(09)70096- 8
  • 4. Pandey S, Chandravati C. Human papillomavirus-mediated cervical cancer awareness and gardasil vaccination: a pilot survey among north Indian women. J Community Health. 2013;38:907- 10. https://doi.org/10.1007/s10900-013-9697-6
  • 5. Dalstein V, Riethmuller D, Prétet JL, Le Bail CK, Sautière JL, Carbillet JP, et al. Persistence and load of high-risk HPV are predictors for development of high-grade cervical lesions: a longitudinal French cohort study. Int J Cancer. 2003;106(3):396-403. https://doi.org/10.1002/ijc.11222
  • 6. Dong L, Wang MZ, Zhao XL, Feng RM, Hu SY, Zhang Q, et al. Human papillomavirus viral load as a useful triage tool for non- 16/18 high-risk human papillomavirus positive women: a prospective screening cohort study. Gynecol Oncol. 2018;148(1):103- 110. https://doi.org/10.1016/j.ygyno.2017.11.016
  • 7. Luo H, Belinson JL, Du H, Liu Z, Zhang L, Wang C, et al. Evaluation of viral load as a triage strategy with primary high-risk human papillomavirus cervical cancer screening. J Low Genit Tract Dis. 2017;21(1):12- 16. https://doi.org/10.1097/LGT.0000000000000277
  • 8. Li Y, Wang H, Zhang Y, Jing X, Wu N, Hou Y, Hao C. Correlation between Multi-type human papillomavirus infections and viral loads and the cervical pathological grade. Int J Gynecol Obstet. 2021;152(1):96- 102. https://doi.org/10.1002/ijgo.13406
  • 9. Zeng Z, Austin RM, Wang L, Guo X, Zeng Q, Zheng B, Zhao C. Nationwide prevalence and genotype distribution of high-risk human papillomavirus infection in China. Am J Clin Pathol. 2022;157(5):718-23. https://doi.org/10.1093/ajcp/aqab181
  • 10. De Brot L, Pellegrini B, Moretti ST, Carraro DM, Soares FA, Rocha RM, et al. Infections with multiple high-risk HPV types are associated with high-grade and persistent low-grade intraepithelial lesions of the cervix. Cancer Cytopathol. 2017;125(2):138- 143. https://doi.org/10.1002/cncy.21789
  • 11. American Cancer Society, Risk Factors for Cervical Cancer. Available at: https://www.cancer.org/cancer/types/cervical-cancer/causes-risks-prevention/risk-factors.html (Access Date: June 10, 2024).
  • 12. Simen-Kapeu A, KatajaV, YliskoskiM, Syrjänen K, Dillner J, Koskela P, et al. Smoking impairs human papillomavirus (HPV) type 16 and 18 capsid antibody response following natural HPV infection. Scand J Infect Dis. 2008;40(9):745-75. https://doi.org/10.1080/00365540801995360
  • 13. AguayoF, Muñoz JP, Perez-Dominguez F, Carrillo-Beltrán D, Oliva C, CalafGM, et al. High-risk human papillomavirus and tobacco smoke interactions in epithelial carcinogenesis. Cancers. 2020;12(8):2201. https://doi.org/10.3390/cancers12082201
  • 14. Schmitt M, Depuydt C, Benoy I, Bogers J, Antoine J, Arbyn M, Pawlita M. Multiple human papillomavirus infections with high viral loads are associated with cervical lesions but do not differentiate grades of cervical abnormalities. J Clin Microbiol. 2013;51(5):1458-64. https://doi.org/10.1128/JCM.00087- 13
  • 15. Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol. 2012;137(4):516-42. https://doi.org/10.1309/AJCPTGD94EVRSJCG
  • 16. Kim J, Kim M, Park JY. Evaluation of the characteristics of multiple human papillomavirus (HPV) infections identified using the BD Onclarity HPV assay and comparison with those of single HPV infection. J Pathol Transl Med. 2022;56(5):289-93. https://doi.org/10.4132/jptm.2022.08.02
  • 17. Trottier H, Mahmud S, Costa MC, Sobrinho JP, Duarte-Franco E, Rohan TE, et al. Human papillomavirus infections with multiple types and risk of cervical neoplasia. Cancer Epidemiol Biomarkers Prev. 2006;15(7):1274-80. https://doi.org/10.1158/1055-9965.EPI-06-0129
  • 18. Na J, Li Y, Wang J, Wang X, Lu J, Han S. The correlation between multiple HPV infections and the occurrence, development, and prognosis of cervical cancer. Front Microbiol. 2023;14:1220522. https://doi.org/10.3389/fmicb.2023.1220522
  • 19. De Brot L, Pellegrini B, Moretti ST, Carraro DM, Soares FA, Rocha RM, et al. Infections with multiple high‐risk HPV types are associated with high‐grade and persistent low‐grade intraepithelial lesions of the cervix. Cancer Cytopathol. 2017;125(2):138-43. https://doi.org/10.1002/cncy.21789
  • 20. World Health Organization, One in Three Men Worldwide Are Infected with Genital Human Papillomavirus. Available at:https://www.who.int/news/item/01-09-2023-one-in-three-men-worldwide- are-infected-with-genital-human-papillomavirus (Access Date: June 10, 2024).
  • 21. World Health Organization, Human papillomavirus vaccines: WHO position paper, December 2022. Available at: https://www.who.int/publications/i/item/who-wer9750-645-672 (Access Date: June 10, 2024).
There are 21 citations in total.

Details

Primary Language English
Subjects Cancer Biology, Infectious Diseases, Clinical Microbiology, Cancer Diagnosis
Journal Section Original Research
Authors

Gülçin Çetin Uysal 0000-0003-3204-6962

Nil Tekin 0000-0002-9300-2528

Publication Date October 25, 2024
Submission Date May 22, 2024
Acceptance Date August 20, 2024
Published in Issue Year 2024 Volume: 9 Issue: 3

Cite

APA Çetin Uysal, G., & Tekin, N. (2024). Age distribution of patients with multiple High-Risk Human Papilloma Virus (HR-HPV) genotypes and HPV vaccine recommendations by age. Family Practice and Palliative Care, 9(3), 80-84. https://doi.org/10.22391/fppc.1487298
AMA Çetin Uysal G, Tekin N. Age distribution of patients with multiple High-Risk Human Papilloma Virus (HR-HPV) genotypes and HPV vaccine recommendations by age. Fam Pract Palliat Care. October 2024;9(3):80-84. doi:10.22391/fppc.1487298
Chicago Çetin Uysal, Gülçin, and Nil Tekin. “Age Distribution of Patients With Multiple High-Risk Human Papilloma Virus (HR-HPV) Genotypes and HPV Vaccine Recommendations by Age”. Family Practice and Palliative Care 9, no. 3 (October 2024): 80-84. https://doi.org/10.22391/fppc.1487298.
EndNote Çetin Uysal G, Tekin N (October 1, 2024) Age distribution of patients with multiple High-Risk Human Papilloma Virus (HR-HPV) genotypes and HPV vaccine recommendations by age. Family Practice and Palliative Care 9 3 80–84.
IEEE G. Çetin Uysal and N. Tekin, “Age distribution of patients with multiple High-Risk Human Papilloma Virus (HR-HPV) genotypes and HPV vaccine recommendations by age”, Fam Pract Palliat Care, vol. 9, no. 3, pp. 80–84, 2024, doi: 10.22391/fppc.1487298.
ISNAD Çetin Uysal, Gülçin - Tekin, Nil. “Age Distribution of Patients With Multiple High-Risk Human Papilloma Virus (HR-HPV) Genotypes and HPV Vaccine Recommendations by Age”. Family Practice and Palliative Care 9/3 (October2024), 80-84. https://doi.org/10.22391/fppc.1487298.
JAMA Çetin Uysal G, Tekin N. Age distribution of patients with multiple High-Risk Human Papilloma Virus (HR-HPV) genotypes and HPV vaccine recommendations by age. Fam Pract Palliat Care. 2024;9:80–84.
MLA Çetin Uysal, Gülçin and Nil Tekin. “Age Distribution of Patients With Multiple High-Risk Human Papilloma Virus (HR-HPV) Genotypes and HPV Vaccine Recommendations by Age”. Family Practice and Palliative Care, vol. 9, no. 3, 2024, pp. 80-84, doi:10.22391/fppc.1487298.
Vancouver Çetin Uysal G, Tekin N. Age distribution of patients with multiple High-Risk Human Papilloma Virus (HR-HPV) genotypes and HPV vaccine recommendations by age. Fam Pract Palliat Care. 2024;9(3):80-4.
 Download Cover Image

Family Practice and Palliative Care       ISSN 2458-8865       E-ISSN 2459-1505